Hepatitis B Vaccination Recommendations for Adults
All adults aged 19-59 years should receive the hepatitis B vaccine, regardless of risk factors. 1
Age-Based Vaccination Strategy
Adults 19-59 Years
- Universal vaccination is recommended for all adults in this age group 1
- This represents a shift from the previous risk-based approach to a universal strategy
- No need to identify specific risk factors—providers should offer vaccination to everyone in this age bracket
- This change was driven by cost-effectiveness data showing an ICER of $117,000 per QALY gained and the recognition that risk-based approaches led to suboptimal coverage 1
Adults ≥60 Years
The approach differs based on risk status:
Should receive vaccination (strong recommendation):
- Adults with any risk factors for hepatitis B 1
May receive vaccination (permissive recommendation):
- Adults without known risk factors 1
- The language "may receive" is intentional—it shifts responsibility from patient request to provider offering, but acknowledges lower disease incidence (0.6 cases per 100,000) in this age group 1
Specific High-Risk Groups Who Should Receive Vaccination
Regardless of age, these groups warrant vaccination 1:
Sexual Exposure Risk
- Sex partners of HBsAg-positive persons
- Sexually active persons not in long-term monogamous relationships (>1 partner in 6 months)
- Persons seeking STI evaluation/treatment
- Men who have sex with men
Blood/Percutaneous Exposure Risk
- Current or recent injection drug users
- Household contacts of HBsAg-positive persons
- Healthcare and public safety workers with blood exposure risk
- Residents and staff of developmental disability facilities
- Dialysis patients (hemodialysis, peritoneal dialysis, predialysis)
Medical Conditions
- Persons with hepatitis C infection
- Persons with chronic liver disease (cirrhosis, fatty liver, alcoholic liver disease, autoimmune hepatitis, ALT/AST >2× upper limit normal)
- Persons with HIV infection
- Persons with diabetes (at clinician's discretion)
Other Exposures
- International travelers to areas with HBsAg prevalence ≥2%
- Incarcerated persons
Important Clinical Caveats
Do NOT revaccinate if:
- Patient completed a vaccination series previously (documented with dated records only)
- Patient has history of HBV infection
- Exception: Specific populations may need revaccination per 2018 ACIP guidelines (nonresponder infants born to HBsAg-positive mothers, healthcare providers, hemodialysis patients) 1
Pre-vaccination testing considerations:
- In populations with high rates of previous HBV infection, pre-vaccination testing (HBsAg, anti-HBs, anti-HBc) may reduce costs by avoiding unnecessary vaccination of immune individuals 1
- Testing can be performed simultaneously with first vaccine dose
- Vaccinating already-immune persons is not harmful 1
Rationale for Universal Adult Vaccination
The shift to universal vaccination for ages 19-59 addresses several critical issues:
- Risk-based approaches failed: Previous strategies requiring risk factor identification resulted in persistently low coverage—only 30% of US adults are vaccinated 2
- Patients don't disclose risk factors: Approximately two-thirds of chronically infected persons are unaware of their diagnosis 2
- Racial disparities: In 2019, HBV infection rates among non-Hispanic Black adults were triple those of Asian/Pacific Islander adults 1
- Proven effectiveness: Universal vaccination in children eliminated disparities and dramatically reduced disease burden 1
This evidence-based approach prioritizes prevention of a disease with substantial morbidity and mortality, recognizing that identifying individual risk factors in clinical practice has proven impractical and ineffective.